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Cells of the osteoblast lineage affect homing, 1, 2 number of long term repopulating hematopoietic 
stem cells (HSCs) 3, 4, HSC mobilization and lineage determination and B lymphopoiesis 5-8. 
More recently osteoblasts were implicated in pre-leukemic conditions in mice 9, 10. Yet, it has not 
been shown that a single genetic event taking place in osteoblasts can induce leukemogenesis. We 
show here that in mice, an activating mutation of β-catenin in osteoblasts alters the differentiation 
potential of myeloid and lymphoid progenitors leading to development of acute myeloid leukemia 
(AML) with common chromosomal aberrations and cell autonomous progression. Activated β-
catenin stimulates expression of the Notch ligand Jagged-1 in osteoblasts. Subsequent activation 
of Notch signaling in HSC progenitors induces the malignant changes. Demonstrating the 
pathogenetic role of the Notch pathway, genetic or pharmacological inhibition of Notch signaling 
ameliorates AML. Nuclear accumulation and increased β-catenin signaling in osteoblasts was also 
identified in 38% of patients with MDS/AML. These patients showed increased Notch signaling in 
hematopoietic cells. These findings demonstrate that genetic alterations in osteoblasts can induce 
AML, identify molecular signals leading to this transformation and suggest a potential novel 
pharmacotherapeutic approach to AML.
Mice expressing a constitutive active β-catenin allele in osteoblasts, (βcat(ex3)osb), are 
osteopetrotic11, and die before 6 weeks of age (Fig. 1a) of unknown reasons. Upon further 
examination βcat(ex3)osb mice were anemic at 2 weeks of age with peripheral blood 
monocytosis, neutrophilia, lymphocytopenia and thrombocytopenia (Extended Data Fig. 1a). 
Erythroid cells were decreased in the marrow and extramedullary hematopoiesis was 
observed in the liver (Fig. 1c and Extended Data Fig. 1b,l,m). Although the number of 
myeloid (CD11b+/Gr1+) cells decreased due to osteopetrosis, their relative percentage 
increased suggesting a shift in the differentiation of HSCs to the myeloid lineage (Fig. 1d 
and Extended Data Fig. 1c,d). The hematopoietic stem and progenitor cell (HSPC) 
population in the bone marrow (Lin-Sca+c-Kit+, LSK) cells decreased 2-fold in βcat(ex3)osb 
mice, but their percentage was 2-fold greater than in WT littermates (Fig. 1e and Extended 
Data Fig. 1e,f). The long term repopulating HSC progenitors (LT-HSCs), increased in 
numbers and percentage whereas the lymphoid-biased multipotential progenitors, LSK+/
FLT3+, and the granulocyte/monocyte progenitors (GMP) (Extended Data Fig. 1g-j) 
decreased. The GMP percentage increased (Fig. 1f). Identical abnormalities were observed 
in the spleen of βcat(ex3)osb mice (Extended Data Fig. 1n-p). The mutation was introduced 
in osteoblasts but not in any cells of the hematopoietic compartment (Extended Data Fig.1q-
t) of βcat(ex3)osb mice.
Blasts (12-90%) and dysplastic neutrophils (13-81%), were noted in the blood and there was 
dense and diffuse infiltration with myeloid and monocytic cells, blasts (30%-53% for n=12 
mice) and dysplastic neutrophils in the marrow and spleen of βcat(ex3)osb mice (Fig. 1g-k, 
Extended Data Fig. 2a-c). In the liver, clusters of immature cells with atypical nuclear 
appearance were seen (Fig. 1l). The increase in immature myeloid cells was confirmed by 
staining with myeloid markers in bones, spleen and liver, (Extended Data Fig. 2d-h). 
Reduced B-lymphopoiesis without changes in T-cell populations was observed in 
βcat(ex3)osb mice (Extended Data Fig. 2i-t). Differentiation blockade was demonstrated by 
the presence of immature myeloid progenitors in βcat(ex3)osb marrow and differentiation 
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cultures (Fig. 1m-n and Extended Data Fig. 2u-x). These cellular abnormalities fulfill the 
criteria of AML diagnosis in mice 12 with principle features of human AML 13, 14.
A clonal abnormality involving a Robertsonian translocation Rb(1;19) was identified in 
myeloid cells of the spleen of a βcat(ex3)osb mouse (Extended Data Fig. 2y). Recurrent 
numerical and structural chromosomal alterations were also detected in myeloid cells of the 
spleen of all mutant mice examined (Fig. 2a and Extended Data Table 1). Frequent 
abnormalities were detected in chromosome 5, the mouse ortholog of human chromosome 
7q associated with common cytogenetic abnormalities in MDS/AML patients 15. Whole-
exome sequencing identified 4 non-silent somatic mutations in myeloid cells from 3 
βcat(ex3)osb mice (Fig 2b and Extended Data Fig. 2z), including a recurrent one in tnfrsf21 
and a single somatic mutation in Crb1 previously reported in human AML,16 but which has 
insufficient statistical power to determine if it is a driver or passenger mutation. Hence, 
constitutive activation of β-catenin in osteoblasts facilitates clonal progression and is 
associated with somatic mutations in myeloid progenitors.
Transplantation of bone marrow cells from βcat(ex3)osb leukemic mice into lethally 
irradiated WT recipients induced all features of hematopoietic dysfunction, and AML 
observed in βcat(ex3)osb mice including blasts (15-80%) and dysplastic neutrophils 
(15-75%) in the blood and blasts (30-40%) and abnormal megakaryocytes in the marrow and 
early lethality (Extended Data Fig. 3a-i). Transplantation of WT bone marrow cells to 
lethally irradiated βcat(ex3)osb mice also resulted in AML with early lethality (Extended 
Data Fig. 3j-r). Transplantation of LT-HSCs, but not other hematopoietic populations, from 
βcat(ex3)osb mice to sublethally irradiated WT recipients resulted in AML with early 
lethality (Fig. 2c,d and Extended Data Fig. 3s-z) indicating that LT-HSCs are the leukemia-
initiating cells (LICs). These results demonstrate that osteoblasts are the cells responsible for 
AML development in this model. Remarkably, HSCs of βcat(ex3)osb mice have acquired a 
permanent self-perpetuating genetic alteration that becomes independent of the initial 
mutation in osteoblasts.
All βcat(ex3)osb mice examined develop AML between 2 (40%) and 3.5 (60%) weeks of 
age. Livers of βcat(ex3)osb newborn mice show increased LSK cells and cells of the myeloid 
lineage, and a decrease in erythroid and B-lymphoid cells (Extended data Fig. 4a-j). 
Microhypolobated megakaryocytes, Pelger Huet neutrophils, seen in MDS and other 
congenital entities, and nuclear cytoplasmic asynchrony in the erythroid lineage were also 
seen in the liver and bone marrow of newborn βcat(ex3)osb mice while their spleens showed 
increased number of blasts and a shift towards the myeloid lineage (Extended Data Fig. 4k-
m). These characteristics indicate deregulated hematopoiesis with neutrophil dyspoiesis at 
birth. Less than 20% blasts were seen in the marrow, consistent with a diagnosis of MDS 
with excess blasts (RAEB1/2). Differentiation blockade was not observed in newborn 
animals and fetal HSCs did not transfer the disease (Extended Data Fig. 4n-w) due to lack of 
HSC-osteoblast interaction in the fetal liver. These results, confirm that AML is induced by 
defective niche signals that are restricted to the bone marrow osteoblasts.
β-catenin target genes in osteoblasts that may regulate HSC fate were identified by 
microarray analysis. One gene, the Notch ligand Jagged-1, fulfilled 4 criteria: acts on 
Kode et al. Page 3









adjacent cells, activates a pathway many targets of which are increased in the array, has been 
implicated in hematopoiesis and is regulated transcriptionally by β-catenin (Extended Data 
Fig. 5a-d and 17). Accordingly, Jagged-1 expression was increased in βcat(ex3)osb bones and 
expression of the Notch targets Hes1, Hes5, Hey1, Hey2 increased and Hes1 targets Cebpα 
and Pu.1 decreased in βcat(ex3)osb LSK cells of βcat(ex3)osb mice suggesting increased 
Notch signaling in this population (Fig. 3a,b and Extended Data Fig.5a,b,f-g). Notch1 and 2 
expression was not affected (Extended Data Fig. 5e). Increased Notch signaling occurred 
specifically in the leukemia-initiating LT-HSCs without changes in the other LSK 
compartments (Extended Data Fig. 5f-g).
To determine if Jagged-1 in osteoblasts contributes to AML development in βcat(ex3)osb 
mice we removed one allele of Jagged-1 in osteoblasts (βcat(ex3)osb;Jagged1osb+/− mice). 
These genetic manipulation decreased Notch signaling is LSK cells, rescued anemia, and 
deregulation of HSC lineage differentiation and prevented AML development (Fig. 3d-f, 
Extended Data Fig. 6a-j). βcat(ex3)osb;Jagged1osb+/− mice survived and were healthy for 
the entire time they were observed, even though they remained osteopetrotic, (Fig.3g and 
Extended Data Fig. 6k). Similarly, pharmacological inhibition of Notch signaling with a γ-
secretase inhibitor 18 reversed hematopoietic deregulation and myeloid expansion in blood, 
marrow and spleen and reversed AML in βcat(ex3)osb mice without affecting osteopetrosis 
(Extended Data Figs. 5h-s and 7), indicating that osteopetrosis is not enough to drive AML. 
These observations suggest that Notch signaling is required for AML development in 
βcat(ex3)osb mice and that chromosomal alterations may result from increased Notch 
signalling19. Alternatively, healthy HSCs in the endothelial and perivascular niche can 
multiply and outgrow leukemic HSCs in DBZ-treated βcat(ex3)osb mice. Jagged1 is required 
for leukemia induction; whether it is involved in leukemia maintenance with a therapeutic 
benefit, remains to be examined.
To assess the relevance of these findings to humans we examined activation of β-catenin 
signaling in bone marrow biopsies from MDS or AML patients. Forty-one out of 107 
patients examined with all MDS subtypes, AML, or MDS that had transformed to AML 
(38.3%) showed nuclear localization of β-catenin in osteoblasts (Fig. 4a,b Extended Data 
Fig. 8a-h and 9h and Supplementary Table 1) but in none of the 56 healthy controls 
examined (Fig. 4c and Extended Data Fig. 9a-g,i,j). Myeloid and erythroid cells and 
megakaryocytes in all patients and healthy controls subjects showed membrane staining for 
β-catenin. Notch signaling was specifically activated only in patients with nuclear 
accumulation of β-catenin as indicated by Hey-1 nuclear staining in their hematopoietic cells 
(Fig. 4d and Extended Data Fig. 8a-f). Expression of all examined β-catenin target genes and 
JAGGED-1 and DLL-1 was upregulated over 2-fold in osteoblasts from MDS/AML patients 
with β-catenin nuclear accumulation in osteoblasts (Fig. 4h, i) but not in healthy controls. 
Notch activity was increased in hematopoietic cells from the same patients, but not healthy 
controls, as indicated by 2-fold increase in the expression of Notch transcriptional targets 
(Fig. 4j). It is possible that, aberrant β-catenin signalling in osteoblasts of these patients may 
be the consequence of hematopoietic clones remodelling the microenvironment as recently 
reported20. During screening assumed healthy controls, 2 individuals had nuclear β-catenin 
in osteoblasts. Re-evaluation showed that one patient developed MDS and the second an 
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underlying MPN/MDS, a pre-AML condition with features of both a myeloproliferative 
neoplasm (MPN) and MDS (Extended Data Fig. 8g, h) suggesting a potential prognostic 
value.
Notch activation promotes expansion of myeloid cells 21 and AMKL-like disease in mice 22. 
Other studies show that the Notch pathway may act as tumor suppressor in AML 23-25 . 
However, in these models, LICs are found in GMPs whereas in our model LICs are in LT-
HSCs suggesting that different LICs can have distinct consequences. Additionally, increased 
Jagged-1 expression may not elicit identical outcomes as increased Notch signaling by all 
Notch receptors 26-28 and βcat(ex3)osb osteoblasts may stimulate additional signals that act 
in combination with Notch to induce mutations contributing to AML. Notch also has a role 
in T-ALL pathogenesis 29. but T-cell specific cooperative signals seem to be required to 
induce transformation 30.
The notion that osteolineage cells can induce myeloid malignancies was previously 
introduced10. Our observations that osteoblasts determine the appearance of cell-
autonomous AML with 100 % penetrance and the molecular and genetic dissection of how 
this occurs in mice and humans demonstrate the role of the marrow niche as a determinant 
of hematological disorders. They may also be informative about MDS/AML pathogenesis in 
humans and expand the potential of new therapeutic applications.
Methods Summary
Mice
Generation of α1(I)Collagen-Cre [α1(I)Col-Cre], Catnb+/lox(ex3), βcat(ex3)osb and 
Jagged-1fl/fl mice has previously been reported. All the protocols and experiments were 
conducted according to the guidelines of the Institute of Comparative Medicine, Columbia 
University.
Patient samples
Bone marrow biopsies from patients with AML and MDS were consecutively obtained from 
2000-2008 and reviewed under a research exempt waiver approved by the institutional 
review boards (IRB) of Memorial Sloan Kettering Hospital and Columbia University and 
Human Biospecimen Utilization Committee.
More details in Full Methods in Supplementary Information.
Methods
Animals
Generation of α1(I)Collagen-Cre [α1(I)Col-Cre], and Catnb+/lox(ex3) mice has previously 
been reported 31-33. Catnb+/lox(ex3) mice, express a β-catenin mutant allele in which exon 3, 
encoding all serine and threonine residues phosphorylated by glycogen synthase kinase 
3β(GSK-3β) (Logan and Nusse, 2004), is flanked by loxP sites. Mice with osteoblast-
specific constitute activation of β-catenin were generated by crossing Catnb+/lox(ex3) mice 
with α1(I)Col-Cre mice expressing Cre under the control of 2.3 kb of the proximal promoter 
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of the mouse pro- α1(I)Collagen gene. The transgene is expressed at high levels in 
osteoblasts specifically 34. There is no expression in chondrocytes, condensed mesenchymal 
cells, perichondrial or periosteal fibroblasts, or any other type I collagen-producing cells, or 
other fibroblast-rich tissues such as muscle, heart or tendons. The resulting offspring, termed 
βcat(ex3)osb, express a constitutive active β-catenin allele in osteoblasts. Mice with 
osteoblast-specific deletion of Jagged-1 were generated by crossing previously described 
Jagged1fl/fl mice 35 with α1(I)Col-Cre mice. Genotyping was performed at weaning stage by 
PCR analysis of genomic DNA. In each experiment the mice used were of the same genetic 
background as they were all littermates. Female mice at 1 month of age were used for the 
bone histomorphometric analysis. βcat(ex3)osb mice lack teeth due to osteopetrosis and 
therefore were fed a normal powdered diet that contained all the required nutrients (20% 
protein, 3.0 ppm Folic Acid, 51 mcg/kg B12 from PicoLab Rodent Diet 20, Cat. Nu. 5053). 
Folate and B12 levels in their blood were normal (folate > 24 ng/ml and B12 > 1,000 pg/ml) 
confirming adequate intake of critical nutrients. Folate and B12 levels were measured by 
Antech Diagnostics using a chemiluminescence-based kit (Siemens). All the protocols and 
experiments were conducted according to the guidelines of the Institute of Comparative 
Medicine, Columbia University.
Patient samples
Bone marrow biopsies from patients with AML and MDS were consecutively obtained from 
2000-2008 and reviewed under a research exempt waiver approved by the institutional 
review board (IRB) of Memorial Sloan Kettering Hospital and Human Biospecimen 
Utilization Committee. Bone marrow biopsies and aspirates obtained from Columbia 
University from patients with MDS and AML were stored in IRB-approved Tissue 
Repository at Columbia University Medical Center after informed consent. This study was 
conducted under protocol approval from the IRB for use of samples from the Tissue 
Repository.
Karyotype analysis
Metaphase chromosome preparations were prepared from cells obtained from spleen 
specimens from βcat(ex3)osb mice after overnight culture in complete RPMI medium using 
standard methods. Giemsa banding was performed and the images were captured using 
Cytovision Imaging system (Applied Imaging, Santa Clara, CA) attached to a Nikon 
Ecliplse 600 microscope. Twenty to 30 karyotypes were prepared from each sample and 
described using the standard chromosome nomenclature for mice.
Array comparative genomic hybridization (aCGH)
aCGH analysis was performed in the spleen of βcat(ex3)osb mice using the Mouse genome 
CGH 244A Platform (Agilent Technologies) according to the manufacturer's instructions. In 
brief, spleen DNA from wild type littermates was used as reference DNA. Genomic DNA 
was subjected to restriction digestion prior to labeling and purification (SureTag DNA 
labeling kit, Agilent Technologies). For each 244 K array, 2 μg of labeled DNA and 2 μg of 
germline reference DNA were labelled with Cy5 and Cy3, respectively. Differentially 
labeled test (tumor) DNA and normal reference DNA were hybridized simultaneously to 
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normal chromosome spreads. Data extraction was conducted using the Agilent feature 
extraction software. Data files were analyzed using the Agilent DNA analytics software. 
Data were deposited in Gene Expression Omnibus (Accession Number GSE51690)
Whole-exome capture and massively parallel sequencing, sequence mapping and 
identification of tumor-specific variants
For three tumor and three unpaired normal samples, purified genomic DNA (3 μg) was 
enriched in protein-coding sequences using the SureSelect Mouse All Exon kit (Agilent 
Technologies) following standard protocols. The resulting target-enriched pool was 
amplified and subjected to paired-end sequencing (2×100 bp) by using HiSeq2000 
sequencing instruments. Exome capture and sequencing procedures were performed at 
Agilent Technologies. Sequencing reads were mapped to the reference genome mm10 using 
the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9 36. We identified sites 
that differed from the reference genome (called here variants) and constructed empirical 
priors for the distribution of variant frequencies in each sample independently. We obtained 
high-credibility intervals (posterior probability ≥1–10−5) for the observed frequency of the 
variants using the SAVI (Statistical Algorithm for Variant Identification) algorithm 37.
Variants were considered absent if found with a frequency between 0 and 2%, and were 
considered present if detected with a frequency above 15%. We chose 15% as a cut-off 
given its correspondence with the sensitivity threshold of direct Sanger sequencing. Variant 
total depth was required to be >10× and <300×. Segmenting variants that exist in one case 
only and absent in the other five cases identified regions of possible copy number 
aberrations. We removed the variants found in these regions. We also excluded all silent 
variants and those present in dbSNP database, and focused only on substitution mutations. 
Finally, in the tumor samples, we removed all variants found present in any of the normal 
samples.
The mutations were subjected to validation (present in tumor, absent in normal) by 
conventional Sanger-based re-sequencing analysis of PCR products obtained from tumor 
DNA using primers specific for the exon encompassing the variant. Data were deposited in 
Short Read Archive (Accession Number SRP031981).
Microarray
Total RNA was extracted from primary osteoblasts isolated from mouse calvaria using 
Trizol reagent (Invitrogen). Microarray analysis was performed using the GeneChip 3’ IVT 
Express kit and mouse genome 430 2.0 array gene chips (Affymetrix) according to the 
manufacturer's instructions. In brief aRNA was synthesized from 500 ng of RNA and was 
biotinylated followed by purification and fragmentation using the GeneChip 3’ IVT Express 
kit. Fragmented aRNA was hybridized to Affymetrix mouse genome 430 2.0 array gene 
chips. Following hybridization chips were scanned with a Genechip Scanner 3000 7G 
(Affymetrix). Data were normalized using the Mas5 method 38, and then log2 transformed. 
Data were deposited in Gene Expression Omnibus (Accession Number GSE43242) 39, 
Differential expression was analyzed using the LIMMA 40. We focused on about 20 genes 
which we selected in advance of the analysis. Genes were considered which either are active 
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in AML, are amplified according to our CGH results, activate Notch, or whose transcription 
is induced by Notch. A significance cutoff of a raw p <0.05 was used, as is appropriate for 
small previously-determined genesets 41. Representative probesets of genes whose 
expression changed greater than ± 20% in at least one of the 2 mutants relative to WT 
appear in Supplementary Table 1.
Bone marrow transplantation
For bone marrow transplantation studies, adult, wild type B5.SJL (CD45.1) recipient mice 
(8 weeks of age) were lethally irradiated (10Gy, split dose) and were then transplanted with 
1×105 of total bone marrow cells from βcat(ex3)osb (CD45.2) or wild type B5.SJL (CD45.2) 
mice (4 weeks of age) by retro-orbital venous plexus injection. Engraftment efficiency in 
recipients was monitored by donor contribution of CD45.2+ cells using FACS analysis. For 
reverse experiment, because of the early lethality of βcat(ex3)osb mice,1×105 of total bone 
marrow cells from wild type B6.SJL (CD45.1) mice were transplanted into lethally 
irradiated (600 rads, split dose) newborn (P1) βcat(ex3)osb mice or wild type littermates by 
liver injections. Engraftment efficiency in recipients was monitored by donor contribution of 
CD45.1+ cells using FACS analysis. For HSC and progenitor transplantation studies, 
sublethally (5.5 Gy) irradiated wild type B5.SJL (CD45.1) recipient mice (8 weeks of age) 
were injected with fractionated donor bone marrow subsets isolated from βcat(ex3)osb 
(CD45.2) or wild type B5.SJL (CD45.2) mice (4 weeks of age). Engraftment efficiency in 
recipients was monitored by donor contribution of CD45.2+ cells using FACS analysis.
Treatment of animals with γ-secretase inhibitor
Two-week old βcat(ex3)osb mice or the wild type littermates were treated with vehicle, the 
γ-secretase inhibitor DBZ ((2S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(5-methyl-6-
oxo-6,7-dihydro-5H-dibenzo[b,-d]azepin-7-yl)-propionamide, 2 μmol/kg) daily by 
intraperitoneal injection for 10 days. DBZ is cell-permeable, selective, nontransition sate 
and noncompetitive inhibitor of the γ-secretase complex. DBZ was synthesized to >99.9% 
purity as assessed by LC/MS (Syncom) and suspended in a 0.5% Methocel E4M (wt/vol, 
Colorcon) and 0.1% (vol/vol) Tween-80 (Sigma) solution 42. Immediately before 
intraperitoneal injection, DBZ was sonicated for 2 minutes to achieve a homogenous 
suspension.
Hematological measurements and peripheral blood morphology
For hematological measurements, blood was collected by cardiac puncture. Peripheral blood 
cell counts were performed on a FORCYTE Hematology Analyzer (Oxford Science Inc.). 
For morphological assessment, peripheral blood smears were stained with Wright-Giemsa 
stain (Sigma-Aldrich) for 10 minutes followed by rinsing in dH2O for 3 minutes. Images 
were taken using a 60x objective on a Leica microscope outfitted with camera.
Real-time PCR
Total RNA was isolated from LSK or hematopoietic cells using RNAeasy micro Plus kit 
(Quiagen). Total RNA from bone marrow-free long bones was isolated using TRIzol reagent 
after removal of the periosteal layer. Quantitative real-time PCR was performed using the 
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SYBR Green Master Mix (Bio-Rad) as previously described 33. β-Actin was used as 
endogenous control. Gene expression in LT-HSCs, ST-HSCs and MPPs was performed 
using the Power Syber Green Cells-to –CT kit (Ambion Life Technologies)
Reporter constructs and luciferase assays
The Jagged-1 promoter region carries multiple potential TCF/LEF binding sites (C/
TCTTTG) located up to nucleotide −4075 (4075, −3072, −2626, −2578, −2343, −1992, 
1957, −1566, −1221, −782). The mouse reporter constructs −4112/+130 and −2100/+130 for 
Jagged-1-luc were generated by PCR amplification of the corresponding fragments using 
mouse genomic DNA as template and subsequent subcloning into the BglII and KpnI-BglII 
sites of the pGL3Basic vector (Promega), respectively. Transient transfection assays were 
performed in HEK293T using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's instructions. Cells were seeded in 24 well plates at a density of 0.3×105 cells/
well. 24h later, cells were transfected with a total amount of 350ng of DNA containing 
150ng reporter plasmid and 50 ng β-catenin and TCF-1 expression vectors. 5ng of pRL-
CMV Renilla (Promega) was used as an internal control to normalize for transfection 
efficiency and equivalent amounts of DNA were achieved with pcDNA3 vector. Forty hours 
after transfection luciferase activity was determined using the Dual Luciferase Reporter 
Assay System (Promega) and quantified using Fluostar Omega (BMG Labtech Inc). 
Luciferase activity is presented as fold induction over basal conditions normalized to empty 
luciferase vector for identical experimental conditions.
Chromatin Immunoprecipitation (ChiP) assay
Primary osteoblasts were seeded in 10 cm dishes at a density of 5 ×106. Cells were cross-
linked with 1% formaldehyde for 10 min. Following Dounce homogenization, nuclei were 
collected and sonicated on ice to an average length of 0.5 kb. The samples were centrifuged 
and precleared with protein G in the presence of sonicated λDNA and bovine serum albumin 
for 2 h at 4 °C. One-tenth of the volume of supernatant was used as input, and the remaining 
volume was immunoprecipitated with β-catenin antibody and the immune complexes were 
collected by absorption to protein G-sepharose, washed, eluted from the beads and incubated 
for 5 h at 65 °C to reverse cross-links. After treatment with proteinase K, DNA was 
extracted with phenol-chloroform and precipitated with ethanol. Immunoprecipitated 
chromatin was analyzed by PCR using primers corresponding to TCF/LEF binding sites on 
the Jagged-1 promoter (−4075, −3072, −2626, −2578, −2343, −1992, −1957, −1566, −1221, 
−782). Putative binding elements were identified by using the TRANSFAC database. The 
products of the PCR amplifications were analyzed by agarose gel electrophoresis.
Antibodies and Flow Cytometry analysis
Freshly isolated bone marrow cells and spleen cells were resuspended in flow-staining 
buffer (PBS plus 2% FBS) and the primary conjugated antibodies were added. After 30 
minutes incubation at 4°C, the cells were then washed twice before flow cytometry analysis. 
The following monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) , 
Allophycocyanin (APC) phycoerythrin (PE) , PE-Cy7, APC-CY7, Per-CPCY5.5, Pacific 
Blue, and Alexa 700 were used: CD117 (c-kit; 2B8), Sca-1 (D7), Mac-1α (M1/70), 
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Gr-1(RB6-8C5), TER-119, (Ly-76) B220 (CD45R), CD19 (1D3), IgM (R6-60.2), CD3 
(17A2), CD4 (RM4-5), CD8a (53-6.7), CD34 (RAM34), CD45 (30-F11), CD31 (MEC 
13.3), CD16/CD32 (FcγRII/III; 2.4G2), CD135 (A2F10.1), CD150 (9D1), CD71 (C2), 
CD45.2 (104), CD45.1 (A20), F4/80. Non-phospho (Active) β-Catenin (S33/S37/T41) 
antibody, IL-7Rα (SB199), Jagged-1 (C-20) (Cell Signaling; D13A1). Seven-color flow 
cytometry acquisition was performed using a LSR II flow cytometer (Becton Dickinson) and 
analysis using FLO-JO software (Treestar, Inc). Cells were gated for size, shape and 
granularity using forward and side scatter parameters. The positive populations were 
identified as cells that expressed specific levels of fluorescence activity above the 
nonspecific auto fluorescence of the isotype control. Nonspecific binding was reduced by 
preincubation with unconjugated anti-FcRII/III (2.4G2). Osteoblasts from MDS/AML 
patients or healthy subjects were idemtified as CD34-/Lin-OCN+ cells, (OCN: osteocalcin 
an osteoblast-specific protein used for isolation of live osteoblastic cells). For Flow sorting 
bone marrow, spleen and thymus cells were resuspended in flow staining buffer at 1 × 
106/ml and labeled with the appropriate conjugated antibodies. After 30 minutes incubation, 
cells were washed twice using flow buffer. Flow sorting was performed using FACSAria 
(Becton Dickinson). Sorted populations were subsequently cultured or stored in RLT buffer 
at −80 °C for later extraction of RNA. Fluorescence intensity plots were presented in log 
scale. All flow cytometry data are representative of five independent experiments.
Clonogenic Assay
Bone marrow cells from 4-week old βcat(ex3)osb or wild type mice were cultured in 
DMEMα with 10% FBS in the presence of 10 ng/ml of GM-CSF or M-CSF or G-CSF for 7 
days. An aliquot of the cells was used to prepare Cytospins and stained with Giemsa to 
identify blasts. A second aliquot was analyzed by flow cytometry for expression of F4/80, 
CD11b and Gr1.
Isolation and counting of osteoblasts from murine and human bone
The periosteal layer was removed from murine tibia and femurs, the remaining bone was 
crushed and washed to remove the bone marrow and bone pieces were digested with 
Collagenase type III. Osteopetrosis in βcat(ex3)osb mice does not allow the use of only 
endosteal bone due to dispersion in the marrow space of irregular trabecular units. Human 
bone biopsies were dissected into pieces and fat and clot was removed from bone chips and 
a 3 mm section was transferred into 500 μl αMEM with 1% Pen/Strep. Scissors were used to 
cut the bone chip into a slurry and then the slurry was digested in 500uL FBS-free αMEM 
(1% Pen/Strep) and 4mg/mL Collagenase type III (Worthington) for final concentration of 
2mg/ml. After incubation for 1 hour with intermittent vortexing, slurry was frozen live for 
later use in 90% FBS with 10% DMSO. For flow cytometry analysis, osteoblasts were 
identified from the digested bone samples as a population of CD34−Lin−Ocn+ cells, where 
OCN (osteocalcin) is an osteoblast-specific, non-nuclear protein commonly used for 
isolation of live osteoblastic cells 43-45. For microarray analysis and for experiments in mice, 
all gene expression studies were repeated using calvaria-derived cells a population rich in 
committed osteoblast progenitors and routinely used as osteoblast-representative. Primary 
murine osteoblasts were prepared from calvaria of 2 day-old pups as previously 
described 46, 47. Mice calvaria were sequentially digested for 20, 40, and 90 min at 37°C in a 
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modified minimal essential medium (GIBCO)–10% FBS containing 0.1 mg of collagenase P 
(Worthington) per ml and 0.25% trypsin (Gibco). Cells of the first two digests were 
discarded, whereas cells released from the third digestion were plated in a minimal essential 
medium–10% FBS.
Osteoblasts were counted in each human bone biopsy as defined by standard 
histomorphometry guidelines 48-50. The number of osteoblasts per mm of bone surface is 
calculated. The number of osteoblasts counted depends on the size of the sample and the 
bio-/pathophysiological characteristics of the individual and for this study, the size of the 
biopsy (1cm) allowed for counting of 30 osteoblasts per biopsy.
Histological analysis of human biopsies and murine bone, spleen and liver
Bone marrow biopsies were fixed overnight in 10% neutral formalin solution, decalcified 
embedded in paraffin and sectioned at 5 μm per standard laboratory protocol. Sections were 
stained for β-catenin using a monoclonal antibody (1:1000, BD Transduction Lab) or for 
Runx2 using a polyclonal antibody (1:100 dilution, Santa Cruz) or for Hey1 using a 
polyclonal antibody (1:300 dilution, Abcam) on an automated Ventana Discovery XT 
(Tuscon, AZ) platform according to manufacturer's instructions. Immune complexes formed 
were developed using a DAB Map Kit (Ventana, Tuscon, AZ). Murine long bones, spleen 
and liver were collected from one month old mice, fixed overnight in 10% neutral formalin 
solution, embedded in paraffin, sectioned at 5 μm, and stained with haematoxylin and eosin 
(H&E). For immunohistochemistry, specimens were incubated with CD-117 (C-kit; 
Abcam), CD13 (Santa Cruz) or Myeloperoxidase (MPO) antibodies after an antigen 
retrieval step and blocking of endogenous peroxidase with 3% H2O2. Sections were then 
incubated with biotinylated secondary antibody and immune complexes formed were 
detected using standard Avidin Biotin complex method.
Statistical analysis
All data are represented as mean ± standard deviation. Statistical analyses were performed 
using a one-way ANOVA followed by Student-Newman-Keuls test and a p value less than 
0.05 was considered significant. Time-to-event analysis was used to assess medium survival 
time to death. Kaplan-Meier curves were generated to illustrate time to death, stratified by 
group status. Statistical significance of the between-group difference in the median time-to-
endpoint was assessed by the log-rank test. Statistical analyses were performed using 
XLSTAT (2012.6.02, Addinsoft) and SAS (version 9.2; SAS institute, Inc, Cary North 
Carolina). A p value less than 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Anemia and myeloid lineage expansion in βcat(ex3)osb mice
a, Lethality b, anemia c, decreased erythroid progenitors and increased percentage of d, 
monocytic/granulocytic, e, LSK, f, myeloid progenitor populations in the marrow and g, 
immature monocytic blasts and h, hypersegmented neutrophils in the blood (13-81% 
neutrophils and 12%-90% blasts). i, Bone marrow sections showing micro-megakaryocytes 
with hyperchromatic nuclei and j, blasts. k, In the spleen, cells with large nucleoli (dotted 
arrow) and dysplastic megakaryocytes (white arrow). l, Cluster of immature cells with 
atypical nuclear appearance in the liver. m, Increased percentage of undifferentiated imature 
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myeloid cells in the bone marrow of βCat(ex3)osb mice. n, Lack of myeloid cell 
differentiation in βCat(ex3)osb bone marrow cells. N=8 mice per WT and 12 mice per 
βcat(ex3)osb groups. Results show a representative of five independent experiments, *p < 
0.05 versus WT. Results are mean ± SD. MNC: mononuclear cells.
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Figure 2. AML in βcat(ex3)osb mice
a, Mouse chromosomal ideogram showing areas of genetic gain (red bars) and loss (green 
bars) identified by aCGH in βCat(ex3)osb mice. b, Sequence traces of somatic mutations in 
myeloid malignancies (CD11b+/Gr1+) from 3 βcat(ex3)osb mice. c, Blasts (12%-75%, solid 
arrows) in blood of sublethally irradiated CD45.1 WT mice transplanted with LT-HSCs 
from CD45.2 βcat(ex3)osb mice 4 weeks following transplantation. d, Lethality in WT mice 
transplanted with indicated hematopoietic populations from βcat(ex3)osb. N=7. Results show 
a representative of two independent experiments.
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Figure 3. Inactivation of Jagged-1 in osteoblasts prevents AML in βcat(ex3)osb mice
Expression of a, Jagged-1 in bone, and b, Notch targets in LSK+ cells (n=4). Rescue of c, 
anemia, and proportions of d, myeloid and e, CD11b+/Gr1+ cells in the bone marrow of 
βCat(ex3)osb/Jagged1osb+/− mice. Normal f, blood histology and g, Survival of 
βcat(ex3)osb;Jagged1osb+/− mice. * p < 0.05 versus WT and # p < 0.05 βCat(ex3)osb versus 
βcat(ex3)osb;Jagged1osb+/− mice. N=8. Results show a representative of two independent 
experiments. Results are mean ± SD.
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Figure 4. Nuclear accumulation of β-catenin in osteoblasts and increased Notch signaling in 
human MDS/AML
a-c, Double immunofluorecsence staining for β-catenin and Runx2 in bone marrow biopsies 
from a-b, MDS/AML patients and c, healthy subjects (60X). d, Nuclear accumulation of 
Hey-1 in patient shown in (a). e-g, Flow cytometry detecting nuclear/activated β-catenin. 
Plots show e, nuclear versus f, non-nuclear localization of β -catenin in osteoblasts from 
MDS/AML patients or g, healthy subjects as CD34-/Lin-OCN+ cells, (OCN: osteocalcin). 
In a-g, one representative from 107 patients and one representative from 56 healthy subjects. 
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Increased expression of h, β-catenin targets and i, JAGGED-1 and DLL-1 in CD34−/Lin
−OCN+ osteoblasts and j, Notch targets in CD34+/Lin+OCN− hematopoietic cells from 
MDS/AML patients or healthy subjects. p<0.05 versus patients with non-nuclear β-catenin 
in osteoblasts and healthy subjects. Results are mean ± SD. Results show a representative of 
two independent experiments with N= 3 for healthy subjects, 12 for MDS/AML patients 
with membrane localization of β-catenin and 11 for MDS/AML patients with nuclear β-
catenin.
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Extended Data Figure 1. Anemia, peripheral blood leukocytosis and monocytosis and 
deregulated hematopoiesis specific activation of β-catenin in osteoblasts of β-Cat(ex3)osb mice
a, Hematopoietic parameters. White blood cells (WBC), Red blood cells (RBC), 
Hemoglobin (HB), Hematocrit (HCT), platelets, lymphocytes (LY), Neutrophiles (NE), 
Monocytes (MO) in 2 weeks old mice. b-k, In the bone marrow b, Erythroid cell numbers. 
c, Representative flow cytometry image showing monocytic/granulocytic (CD11b+/Gr1+) 
subset. d, Numbers of the CD11b+/Gr1+ subset. e, Distribution of LSK (Lineage-Sca+C-kit
+) population. f, LSK numbers g, Frequency and h, Percentage of LT-HSCs and ST-HSCs. 
i, Numbers of LSK+/FLT3+ cells. j, Myeloid progenitor profile by CD34-versus-FcgRII/III 
analysis of electronically gated Lin–Sca-1–c-Kit+ bone marrow cells. k, Numbers of 
myeloid progenitor populations. l, Spleen weight. m, Extramedullar hematopoiesis in the 
liver of 3 weeks old βcat(ex3)osb mice indicated by megakaryocytes (solid arrows), myeloid 
(open arrows) and rare erythroid precursors (dotted arrows). Percentage of n, Ter119+, o, 
CD11b+/Gr1+ and p, myeloid progenitor populations in the spleen. q, PCR analysis of 
genomic DNA from osteoblasts and indicated hematopoieic populations from WT and 
βCat(ex3)osb mice. r-t, Real-Time PCR analysis of b-catenin targets in r, bone marrow 
CD45+CD34+CD31+ cells, s, spleen and t, bones. In a N=6, b-k, n-p N=8, l, m N=5, and r-t 
N=4 mice per group. Results are mean ± SD and show a representative from five (a-p) or 2 
(q-t) independent experiments. *p < 0.05 versus WT. MNC: mononuclear cells.
Kode et al. Page 21









Extended Data Figure 2. Multi-organ infiltration with blasts and dysplastic cells and myeloid 
differentiation block in βCat(ex3)osb mice
a, Blast infiltration (solid arrows) and neutrophil hypersegmentation (open arrow and 
magnified panels) in the blood of βCat(ex3)osb mice. Images at 40x or 100x. b, Blast 
infiltration (solid arrows) and micro-megakaryocytes with hyperchromatic nuclei (white 
arrows) in the bone marrow of βCat(ex3)osb mice. Images at 60X. c, Blast infiltration (solid 
arrows and magnified panel) and presence of dysplastic megakaryocytes (yellow arrows and 
magnified panel) in the spleen of βCat(ex3)osb mice. Image at 400X. d-f, Myeloperoxidase 
(MPO) staining of d, long bone e, spleen and f, liver showing massive invasion of myeloid 
cells. g, CD117 (C-kit) staining of bone sections showing CD117+ blasts in βCat(ex3)osb 
mice. h, CD13 staining of bone sections showing myeloid/monocytic infiltration in 
βCat(ex3)osb mice. In d-h images at 60X magnification. i-j, B-cell progenitors numbers in 
the i-j, bone marrow, k, spleen and l, lymph nodes.. m-t, Proportion of T-cells. u, Lack of 
myeloid cell differentiation in βCat(ex3)osb bone marrow cells following treatment with 
cytokines. v-x, Percentage of immature myeloid cells in ex vivo bone marrow cultures 
treated with cytokines. y. Robertsonian translocation between chromosomes 1 and 19 in 2 of 
30 metaphases of the spleen of an 18-day old βcat(ex3)osb mouse. Inset shows the same 
abnormality in another cell. z, Whole-exome sequencing of myeloid malignancies (CD11b+/
Gr1+) from 3 cat(ex3)osb mice and 3 germline normal (tail) samples.
In (i-x) N=6, mice per group. *p < 0.05 versus WT. Results are mean ± SD and show a 
representative of five (i-t) or three (u-x) independent experiments.
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Extended Data Figure 3. Cell autonomous AML development by bone marrow and LT-HSCs 
cells of βCat(ex3)osb mice
a, Engraftment efficiency of CD45.2 βCat(ex3)osb bone marrow cells in lethally irradiated 
CD45.1 WT mice 7 weeks following transplantation. b-f, Percentage of indicated 
populations in bone marrow of transplanted mice. g, Blasts in blood (15-80%, solid arrows) 
of lethally irradiated CD45.1 WT mice transplanted with CD45.2 βCat(ex3)osb marrow cells 
7 weeks following transplantation. h, Blasts (solid arrows) and dysplastic megakaryocytes 
(open arrow) in bone marrow of transplanted mice Images at 60x. i, Lethality curves. j, 
Engraftment efficiency of CD45.1 WT bone marrow cells in lethally irradiated CD45.2 
βCat(ex3)osb mice. k-o, Increased percentage of k, LSK cells, l, myeloid progenitors, and m, 
CD11b+/Gr1+ cells and decreases in n, erythroid cells and o, B-lymphopoiesis in the bone 
marrow of transplanted mice. p, Blasts in the blood and q, bone marrow (solid arrows) of 
transplanted mice. Images were taken at o, 100x and p, 60x. r, Lethality curves. s, 
Engraftment efficiency of indicated bone marrow hematopoietic populations from 4-week 
old CD45.2 βCat(ex3)osb or wild type mice in sublethally irradiated CD45.1 WT mice after 
4 weeks (for LT-HSCs, due to lethality) and 8 weeks (for other populations) of 
transplantation. t, Blood counts in wild type mice transplanted mice. u-w, Lack of blasts in 
the blood of wild type mice transplanted with indicated hematopoietic cells from 
βCat(ex3)osb mice. x, Disease development in wild type mice transplanted with indicated 
hematopoietic cells from βCat(ex3)osb mice. y, Splenomegaly in WT mice transplanted with 
LT-HSCs from βcat(ex3)osb. z, Spleen size and weight in WT mice transplanted with 
indicated hematopoietic populations from WT/βcat(ex3)osb mice. N=6 mice per group. 
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Results are mean ± SD and show a representative of two independent experiments. *p < 
0.05 versus WT- WT transplanted group.
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Extended Data Figure 4. Newborn βCat(ex3)osb mice show MDS but fetal HSCs from 
βCat(ex3)osb mice do not transfer AML
a-e, Increased percentage of (a) LSK cells, (b) GMPs, and (c) CD11b+/Gr1+ cells and 
decreases in (d) erythroid cells and (e) B-lymphopoiesis in the liver of newborn (P1) 
βCat(ex3)osb mice. f-j, Increased percentage of (f) LSK cells, (g) GMPs, and (h) CD11b+/
Gr1+ cells and decreases in (i) erythroid cells and (j) B-lymphopoiesis in the bone marrow 
of newborn (P1) βCat(ex3)osb mice. k, Liver, l, bone marrow and m, spleen of of newborn 
(P1) βCat(ex3)osb mice showing microhypolobated megakaryocytes (open arrows), Pelger 
Huet neutrophils (yellow arrows) or blasts (solid arrows) Images at 100x. n, Percentage of 
imature myeloid cells in the bone marrow of newborn mice. o-t, Flow cytometry and 
Giemsa-stained cytospins showing lack of changes in the percentage of immature myeloid 
cells in ex vivo cultures of bone marrow cells from P1 stage βCat(ex3)osb mice and treated 
with indicated cytokines. u, Engraftment efficiency of CD45.2 βCat(ex3)osb LSK cells 
obtained from the liver of embryonic day 18.5 embryos in sublethally irradiated CD45.1 WT 
mice. v, Normal peripheral blood measurements in transplanted mice. w, Lack of blasts in 
the blood of transplanted WT mice. Images at 100x. N=6 mice per group. Results are mean 
± SD and represent at least two independent experiments. *p < 0.05 versus WT.
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Extended Data Figure 5. Inhibition of increased Notch signaling normalizes blood counts and 
rescues hematopoietic defects in βCat(ex3)osb mice
a, Microarray analysis of calvaria-derived osteoblasts from βCat(ex3)osb mice. AML and 
Notch-related genes in βCat(ex3)osb osteoblasts and with p<0.05 and fold change of ± 20% 
in one comparison. Genes which that are up- or down-regulated relative to WT are shown. 
b, Flow cytometry analysis of Jagged-1 expression in osteoblasts (MFI: mean fluorescent 
intensity). c, Luciferase activity in HEK293T cells co-transfected with β-Catenin, Lef1 and 
Jagged1-Luc reporter constructs (−4112/+130) and (−2100/+130). Results show fold 
induction over respective Jagged1-Luc reporter constructs. * p< 0.05 versus respective 
Jagged1-Luc. Results are mean ± SD. d, ChIP in primary osteoblasts using anti-β-catenin 
antibody. Primers spanned the putative TCF/LEF binding sites (indicated) on the Jagged-1 
promoter. e, Expression of Notch1 and Notch2 in LSK+ cells. f-g, Expression of Notch 
targets in LSK+ subpopulations. i, Normal intestinal architecture and j, PAS staining 
showing lack of goblet cell (arrows) metaplasia in DBZ-treated mice. Images at 60x. k, 
Peripheral blood counts and bone marrow cellularity in wild type and βCat(ex3)osb mice 
treated daily with vehicle or DBZ (2μmol/kg body weight) for 10 days. l-p, Percentage of k, 
LSK cells, l, LSK+ subpopulations m, myeloid progenitors, n, CD11b+/Gr1+ population, o, 
erythroid cells. m, Percentage of erythroid cells and p, LSK+/FLT3+ population in the bone 
marrow. q-s, Percentage of q, myeloid progenitor populations, r, CD11b+/Gr1+ cells and s, 
erythroid cells in the spleen. In a N=3 mice per group and in b N=4 mice per group. In c,d 
results represent two independent experiments. In (e-g) N=4 mice per group, and *p < 0.05 
versus WT. In (h-s) N=8 mice per group and *p < 0.05 versus WT and # p < 0.05 
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βCat(ex3)osb-vehicle versus DBZ-treated βCat(ex3)osb group. Results are mean ± SD and 
show a representative of two independent experiments.
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Extended Data Figure 6. Jagged-1 inactivation in osteoblasts prevents AML of βCat(ex3)osb mice
a-d, Expression of Notch transcriptional targets in bone marrow LSK subpopulations. 
Rescue of changes in the proportions of e, LSK and f, erythroid cells in the bone marrow of 
βCat(ex3)osb/Jagged1osb+/− mice. g, Improvement of B-lymphopoiesis in 
βcat(ex3)osb;Jagged1osb+/− mice. Normal h, bone marrow, i, spleen and j, liver histology in 
βcat(ex3)osb;Jagged1osb+/− mice. k, Long bone sections. Images at 4X. In (a-d) N=4 and in 
(e-k) N-8 mice per group. *p < 0.05 versus WT and # p < 0.05 versus 
βcat(ex3)osb;Jagged1osb+/− mice. Results are mean ± SD and show a representative of three 
(a-d) and two (e-k) independent experiments.
Kode et al. Page 28









Extended Data Figure 7. Inhibition of Notch signaling reverses AML in βCat(ex3)osb mice
a, Lack of blasts (solid arrows) and, normal neutrophils (right panel) in blood of DBZ-
treated βCat(ex3)osb mice. b-c, Normal megakaryocytes in b, the bone marrow and c, spleen 
and d, Normal spleen histology in DBZ-treated βCat(ex3)osb mice. Yellow arrows indicate 
abnormal cells with large nucleoli and dotted arrow indicates abnormal megakaryocytes in 
βCat(ex3)osb mice; white arrow indicates normal megakaryocytes in DBZ-treated 
βCat(ex3)osb mice. e, Lack of monocyte infiltration in the liver of DBZ-treated βCat(ex3)osb 
mice. Arrow indicates cluster of mononuclear cells. f-h, MPO staining of f, bone marrow g, 
spleen and h, liver. i, Percent of cells staining with MPO in the indicated tissues j, Increased 
survival in DBZ-treated βCat(ex3)osb mice. In a-b images taken at 100x magnification. In c-
g images taken at 60X magnification. k-l, Proportion of B-cell populations in the k, bone 
marrow and l, spleen. m, Long bone sections. Images at 4X. N=6 mice per group. *p < 0.05 
versus WT and # p < 0.05 βCat(ex3)osb-vehicle versus DBZ-treated βCat(ex3)osb group. 
Results are mean ± SD and show a representative from two independent experiments.
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Extended Data Figure 8. Nuclear accumulation of β-catenin in osteoblasts and increased Notch 
signaling in 38.3 % of patients with MDS/AML; and identification of underlying pre-AML 
conditions by nuclear localization of β-catenin in osteoblasts
a-f, Double immunofluorecsence staining with β-catenin and Runx2 in osteoblasts from 
bone marrow biopsies from 6 MDS/AML patients harboring nuclear accumulation of β-
catenin in osteoblasts and showing nuclear accumulation of Hey1 in the corresponding 
patients (60X). g-h, During screening assumed healthy controls, 2 individuals were 
identified with nuclear β-catenin in their osteoblasts. Re-evaluation showed underlying 
hematologic disorder, Case 1: MDS RAEB-1, Case 2: Jak2 positive myelofibrosis. g, 
Double immunofluorecsence staining with β-catenin and Runx2 in osteoblasts from bone 
marrow biopsies of the 2 cases (60X). h, β-catenin cellular localization in cases 1 and 2 with 
associated cytogenetic abnormalities. NL: normal cytogenetics. In the 4th column 
percentages indicate osteoblasts with nuclear localization of β-catenin.
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Extended Data Figure 9. Membrane accumulation of β-catenin in osteoblasts in 61.7 % of 
patients with MDS/AML and in healthy subjects and Nuclear accumulation of β-catenin in 
osteoblasts in 38.3 % of patients with MDS/AML identified by flow cytometry
Double immunofluorecsence staining with β-catenin and Runx2 in osteoblasts from bone 
marrow biopsies from a-c, 3 MDS/AML patients and d-g, 4 healthy subjects harboring 
membrane localization of β-catenin in osteoblasts. h-j, Flow cytometry using a non-phospho 
β-catenin antibody detecting nuclear/activated β-catenin. Representative plots showing h, 
nuclear versus i, non-nuclear localization of β -catenin in osteoblasts from individual 
MDS/AML patients and, non-nuclear localization of β-catenin in osteoblasts from 5 healthy 
subjects as CD34−/Lin−OCN+ cells, (OCN, osteocalcin an osteoblast-specific protein used 
for isolation of live osteoblastic cells).
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